Comparison of the Inhibitory Effect Against Copper Ion–Induced Oxidation in Rat Plasma After Oral Administration of Salvianolic Acid B and Its Decocted Solutions

2013 ◽  
Vol 16 (3) ◽  
pp. 239-245 ◽  
Author(s):  
Hyoung Jae Lee ◽  
Jeong-Yong Cho ◽  
Jae-Hak Moon
Keyword(s):  
Oral Administration ◽  
Copper Ion ◽  
Inhibitory Effect ◽  
Rat Plasma ◽  
Salvianolic Acid B ◽  
Salvianolic Acid

Inhibitory effect of salvianolic acid B on malondialdehyde-stimulated proliferation of rat hepatic stellate cells in vitro

2006 ◽  
Vol 14 (5) ◽  
pp. 476
Author(s):  
Xiao-Ling Wang ◽  
Ping Liu ◽  
Yun-Hua Cui ◽  
Xu-Dong Hu ◽  
Bo-Qin Li ◽  
...  
Keyword(s):  
Hepatic Stellate Cells ◽  
Stellate Cells ◽  
Inhibitory Effect ◽  
Salvianolic Acid B ◽  
Salvianolic Acid

Metabolic Transformation of DMBA-Induced Carcinogenesis and Inhibitory Effect of Salvianolic Acid B and Breviscapine Treatment

2011 ◽  
Vol 11 (2) ◽  
pp. 1302-1316 ◽  
Author(s):  
Jie Wei ◽  
Guoxiang Xie ◽  
Shuyun Ge ◽  
Yunping Qiu ◽  
Wei Liu ◽  
...  
Keyword(s):  
Inhibitory Effect ◽  
Salvianolic Acid B ◽  
Salvianolic Acid ◽  
Metabolic Transformation

Bioavailability of salvianolic acid B and effect on blood viscosities after oral administration of salvianolic acids in beagle dogs

2009 ◽  
Vol 32 (5) ◽  
pp. 773-779 ◽  
Author(s):  
Dong-Yan Gao ◽  
Li-Mei Han ◽  
Li-Hong Zhang ◽  
Xiao-Ling Fang ◽  
Jian-Xin Wang
Keyword(s):  
Oral Administration ◽  
Salvianolic Acid B ◽  
Beagle Dogs ◽  
Salvianolic Acid ◽  
Salvianolic Acids

Simultaneous Determination of Imatinib and N-Desmethyl Imatinib in Rat Plasma and Tissues Using LC-MS/MS

2019 ◽  
Vol 15 (2) ◽  
pp. 121-129
Author(s):  
Zhi Rao ◽  
Bo-xia Li ◽  
Yong-Wen Jin ◽  
Wen-Kou ◽  
Yan-rong Ma ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Oral Administration ◽  
Parent Drug ◽  
Gradient Elution ◽  
Biological Tissues ◽  
Rat Plasma ◽  
Running Water ◽  
Liver And Kidney ◽  
The Brain

Background: Imatinib (IM) is a chemotherapy medication metabolized by CYP3A4 to Ndesmethyl imatinib (NDI), which shows similar pharmacologic activity to the parent drug. Although methods for determination of IM and/or NDI have been developed extensively, only few observations have been addressed to simultaneously determine IM and NDI in biological tissues such as liver, kidney, heart, brain and bone marrow. Methods: A validated LC-MS/MS method was developed for the quantitative determination of imatinib (IM) and N-desmethyl imatinib (NDI) from rat plasma, bone marrow, brain, heart, liver and kidney. The plasma samples were prepared by protein precipitation, and then the separation of the analytes was achieved using an Agilent Zorbax Eclipse Plus C18 column (4.6 × 100 mm, 3.5 µm) with gradient elution running water (A) and methanol (B). Mass spectrometric detection was achieved by a triplequadrupole mass spectrometer equipped with an electrospray source interface in positive ionization mode. Results: This method was used to investigate the pharmacokinetics and the tissue distributions in rats following oral administration of 25 mg/kg of IM. The pharmacokinetic profiles suggested that IM and NDI are disappeared faster in rats than human, and the tissue distribution results showed that IM and NDI had good tissue penetration and distribution, except for the brain. This is the first report about the large penetrations of IM and NDI in rat bone marrow. Conclusion: The method demonstrated good sensitivity, accuracy, precision and recovery in assays of IM and NDI in rats. The described assay was successfully applied for the evaluation of pharmacokinetics and distribution in the brain, heart, liver, kidney and bone marrow of IM and NDI after a single oral administration of IM to rats.

Sign in / Sign up

Export Citation Format

Share Document